From Preparation to Presence: Oxipack’s Pharmaceutical Step Forward in 2026
Pharmaceutical manufacturing is a field where you need to earn your way. Trust is built through consistency, documentation, validation discipline, and an understanding that quality systems must stand up to scrutiny long after a machine is installed. Over the past year, Oxipack has approached pharma with that mindset, viewing it as a long-term strategic commitment.
Looking ahead, that work is moving decisively from preparation into presence in 2025 – through standardisation, validation readiness, disciplined internal processes and customer pilots for input and feedback – now shifts into implementation. 2026 is not only about being ready, but about being visible: showing pharmaceutical manufacturers that Oxipack’s container closure integrity testing (CCIT) platform can withstand scrutiny, operate reliably in production environments and earn trust through direct engagement.
Becoming genuinely pharma-ready
Oxipack’s background is in non-destructive vacuum-based leak detection across food, consumer goods, and other high-throughput packaging environments. The measurement physics were already deterministic and proven. But pharmaceutical manufacturing requires more than reliable measurement. It demands procedural control, traceable data handling, secure audit trails, and operator governance that align with Good Manufacturing Practice (GMP) environments and regulatory expectations.
Over the past year, the focus has been on transforming that technology base into a pharmaceutical-grade Container Closure Integrity Testing (CCIT) platform. That meant standardising software architecture, implementing role-based access controls, ensuring electronic record integrity, developing audit-trail functionality, and shaping workflows that align with validation protocols rather than ad hoc production testing.
At the same time, internal processes have matured to support pharmaceutical customers beyond the machine itself. Documentation structures, support models, training pathways, and knowledge specialisation have all been strengthened to reflect the reality of serving a regulated industry.
The objective has been to not only be compliant but also credible.
From readiness to visibility
Preparation only matters if it translates into market confidence. That is why 2026 marks a shift for us – and pharma is now a clear strategic focus.
A dedicated business development lead has been assigned to pharmaceutical markets to ensure conversations are informed, consistent, and grounded in industry understanding. Ongoing investment in pharma-specific knowledge continues across engineering, software, service, and customer support functions. This is not about offering a machine. It is about providing a long-term capability.
For pharmaceutical manufacturers considering deterministic CCIT but weighing manual pathways, Oxipack is positioning itself as a supplier ready for serious evaluation. The platform is built, and the procedures are in place. Now we move into engagement.
Interpack 2026
Trade shows matter in pharma because credibility is built through direct inspection, discussion, and technical questioning. Groundwork was laid at Pack Expo Chicago 2024 and Pack Expo Las Vegas 2025, where Oxipack first began engaging with packaging and pharmaceutical stakeholders in North America, and provided valuable early exposure. It allowed Oxipack to gather feedback and refine its positioning before stepping onto the global pharmaceutical stage.
Interpack 2026 will be the first major global stage where Oxipack will present its pharmaceutical CCIT platform as a mature solution.
At this event, pharmaceutical manufacturers will be able to see how deterministic vacuum-decay CCIT can operate in a production environment while meeting expectations for data integrity, auditability, and procedural controls. More importantly, they will meet the team behind the system, the people responsible for validation thinking, workflow design, and long-term support.
Exceeding expectations, not just meeting them
Regulators have signalled deterministic CCIT as important. However, what has often been missing is practicality. Systems that are reliable in laboratory settings do not always translate cleanly onto production floors. Validation burdens, workflow disruption, or data integration challenges can slow adoption.
The work we have completed over the past year has been guided by one question. How do we make deterministic CCIT practical for everyday pharmaceutical manufacturing?
The result is a platform designed to integrate into real production environments, support defined procedures, generate traceable records, and reduce reliance on subjective visual tests. It enables more frequent integrity testing without introducing unnecessary waste. It supports risk-based sampling strategies or higher inspection coverage, depending on process needs. And it aligns with digital quality system integration rather than standing apart from it.
This is where Oxipack intends to differentiate not only by meeting pharmaceutical expectations, but also by making compliance easier to implement in practice.
Commitment beyond the installation
In pharmaceutical environments, long-term confidence matters as much as initial performance. Machines require requalification, software updates, training refreshes, and ongoing procedural support. Oxipack has expanded its customer success approach to ensure post-installation engagement remains structured and proactive.
Training materials, service frameworks, and support processes have been reviewed and strengthened in preparation for larger-scale pharma deployment.
Pharma is no longer a future ambition inside Oxipack. It is now an established strategic direction supported by technology, processes, and people prepared for regulated realities.
For pharmaceutical manufacturers exploring deterministic CCIT pathways, Oxipack has done the preparation work. The platform is ready. The commitment is real. And 2026 is the year those capabilities become fully visible.
Leak testing in pharma has always been about proving one fundamental truth. That which is sealed remains sealed. In 2026, Oxipack is ready to prove it alongside the industry.